The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.
 
Charlotte Lemech
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Amgen
 
Warren Joubert
No Relationships to Disclose
 
Andrew Parsonson
Research Funding - BeiGene (Inst); DualityBio (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Multitude Therapeutics (Inst)
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosience; MSD; QiLu Pharmaceutical
 
Rajiv Shinde
Travel, Accommodations, Expenses - AstraZeneca; Bayer
 
Prachi Bhave
Travel, Accommodations, Expenses - MSD
 
Junli Xue
No Relationships to Disclose
 
Yaling Huang
Employment - CStone Pharmaceuticals; Multitude therapeutics
Stock and Other Ownership Interests - CStone Pharmaceuticals
 
Xun Meng
Employment - Multitude Therapeutics
Leadership - Multitude Therapeutics
Stock and Other Ownership Interests - Multitude Therapeutics
Patents, Royalties, Other Intellectual Property - Multitude Therapeutics
 
Shu-Hui Liu
Employment - Multitude Therapeutics
Leadership - Multitude Therapeutics
Stock and Other Ownership Interests - Multitude Therapeutics
Patents, Royalties, Other Intellectual Property - Patent related to Multitude Therapeutics discovery work